BMC Gastroenterology最新文献

{"title":"LINC00634 is a novel prognostic biomarker for colon cancer associated with immune infiltration.","authors":"Haiyan Wang, Yanyan Huang, Lina Zhou, Xiaotong Zhu, Xuan Ye, Yi Cen","doi":"10.1186/s12876-025-04049-w","DOIUrl":"https://doi.org/10.1186/s12876-025-04049-w","url":null,"abstract":"<p><strong>Background: </strong>Colon cancer is a highly heterogeneous and most common malignant tumor of the gastrointestinal tract, which is prone to metastasis in advanced stages, leading to a poor prognosis for patients.</p><p><strong>Methods: </strong>To gain a comprehensive understanding of genes associated with the prognosis of colon cancer, we identified a gene set (DPP7, TRPM5, ASB6, LINC00634 and GABRD) with potential prognostic value via genome-wide overall survival (OS) analysis. Further, LINC00634 was silenced by constructing small interfering RNAs (siRNAs) in Colo-320 cells.</p><p><strong>Results: </strong>Multifactorial Cox regression analysis revealed that LINC00634, TRPM5, age, T and M stages were independent risk factors for the prognosis of colon cancer patients. Nomogram demonstrated that these risk factors had favorable predictive ability for 1-, 3- and 5-year OS in colon cancer patients. In addition, high expression of LINC00634 had a worse prognosis for colon cancer patients compared to TRPM5. In vitro experiments showed that silencing LINC00634 significantly inhibited cell proliferation and migration, and promoted cell apoptosis. Finally, immune infiltration analysis revealed that colon cancer patients with high expression of LINC00634 had lower infiltration levels of myeloid dendritic cells (mDCs) and CD8⁺ T cells in their tumor microenvironment (TME).</p><p><strong>Conclusion: </strong>Our study found that LINC00634 can be used as a novel prognostic and immunological marker for colon cancer.</p>","PeriodicalId":9129,"journal":{"name":"BMC Gastroenterology","volume":"25 1","pages":"533"},"PeriodicalIF":2.5,"publicationDate":"2025-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144717455","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and safety of vedolizumab in elderly and younger patients with moderate-to-severe ulcerative colitis: a retrospective real-world study in China.","authors":"Hao Zhang, Xue-Li Ding, Yong-Hong Xu, Jun Wu, Yue-Yuan Wang, Shu-Xian Liu, Jing Yan, Hua Liu, Zi-Bin Tian, Ai-Ling Liu","doi":"10.1186/s12876-025-04125-1","DOIUrl":"https://doi.org/10.1186/s12876-025-04125-1","url":null,"abstract":"<p><strong>Background: </strong>Limited data exist regarding the efficacy and safety of vedolizumab (VDZ) in China's elderly adult population with ulcerative colitis (UC) in China. In this investigation, a comparative analysis of its efficacy and safety was performed between elderly and younger adult UC cohorts.</p><p><strong>Methods: </strong>Patients with moderate-to-severe UC and at least three VDZ infusions at our clinic between March 2021 and November 2024 were retrospectively recruited. The elderly adult patients (≥ 60 years at first VDZ dose) were matched clinically 1:2 to younger patients (18-59 years).</p><p><strong>Results: </strong>This study included 30 elderly and 60 younger adult patients. There were no significant differences between the two groups regarding sex, body mass index, percentage of smokers, disease duration, disease extent, disease activity, Mayo endoscopic scores, extra-intestinal manifestations, perianal disease, history of bowel-related surgery, or previous and concomitant therapies. At week 6, the clinical remission and steroid-free clinical remission (SFCR) rates were significantly lower (10.00% vs. 33.33%, P = 0.017; 3.33% vs. 26.67%, P = 0.005) in the elderly group than in the younger group, but there was no significant difference in the clinical response rates (P = 1.000). There was no significant difference in the clinical response, remission, and SFCR rates between the two groups at weeks 14, 22, 38, 46, and 54 (P > 0.05). The frequency of adverse events associated with VDZ was comparable between the two groups (33.33% vs. 38.33%, P = 0.643).</p><p><strong>Conclusions: </strong>The efficacy and safety of VDZ in elderly and younger adult patients with UC are similar. Thus, VDZ can be considered both safe and efficacious for treating elderly adult patients with UC.</p>","PeriodicalId":9129,"journal":{"name":"BMC Gastroenterology","volume":"25 1","pages":"531"},"PeriodicalIF":2.5,"publicationDate":"2025-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144706326","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development and validation of a nomogram-based risk prediction model for non-alcoholic fatty liver disease (NAFLD): a logistic regression analysis in a physical examination population.","authors":"Jing Lan, Ting Que, Hong Lan, Mingming Zhang, Lichan Ban","doi":"10.1186/s12876-025-04115-3","DOIUrl":"https://doi.org/10.1186/s12876-025-04115-3","url":null,"abstract":"<p><strong>Background: </strong>The global prevalence of non-alcoholic fatty liver disease (NAFLD) has reached an alarming 25%, based on recent population-based studies. NAFLD diagnosis primarily relies on imaging methods, which may be invasive, costly, or limited. Existing prediction models, such as the Fatty Liver Index (FLI) and NAFLD Liver Fat Score (NLFS), mainly incorporate metabolic parameters from Western populations and neglect non-metabolic factors, limiting their generalizability. To address these limitations, this study developed a screening model integrating both metabolic and non-metabolic indicators, tailored specifically to diverse populations undergoing routine physical examinations.</p><p><strong>Methods: </strong>A retrospective cohort (N = 6,461, 2024) served to construct and validate the NAFLD prediction model, while an external cohort (N = 2,687, 2023) provided additional validation. NAFLD was confirmed by ultrasound. The primary cohort was randomly divided into training (70%) and internal validation (30%) sets. Initially, 20 candidate variables underwent univariate analysis (p < 0.1), and statistically significant variables (p < 0.05) were selected for the final multivariate logistic regression model. Model performance was assessed using area under the curve (AUC), calibration plots, and decision curve analysis (DCA). Robustness was verified through 10 × 10-fold cross-validation and external validation.</p><p><strong>Results: </strong>The final predictive model incorporated 12 predictors (age, sex, body mass index (BMI), uric acid (UA), high-density lipoprotein cholesterol (HDL-C), red blood cell count (RBC), creatinine (Cr), free thyroxine (FT4), aspartate aminotransferase (AST), alanine aminotransferase (ALT), alpha-fetoprotein (AFP), triglyceride-glucose index (TyG)). The model demonstrated excellent discrimination, with a training AUC of 0.909 (95% CI: 0.900-0.919) and internal validation AUC of 0.905 (95% CI: 0.891-0.919). Optimal thresholds were 0.307 in training (sensitivity 78.8%, specificity 86.3%) and 0.205 in validation (sensitivity 88.3%, specificity 77.8%). Calibration was excellent (p = 0.989 training, p = 0.263 validation). DCA indicated substantial net benefits within thresholds from 1 to 98%. External validation confirmed strong model performance regarding discrimination, net benefit, and calibration.</p><p><strong>Conclusion: </strong>This study identified crucial risk factors and constructed a robust NAFLD prediction model suitable for routine physical examination populations, offering clinicians a valuable tool for early disease detection and intervention.</p>","PeriodicalId":9129,"journal":{"name":"BMC Gastroenterology","volume":"25 1","pages":"532"},"PeriodicalIF":2.5,"publicationDate":"2025-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144706325","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction: Accuracy of the diagnosis of gastroesophageal reflux disease by a trial of potassium-competitive acid blocker treatment.","authors":"Peiwen Dong, Lin Lin, Kaidi Sun, Feng Tang, Qian Li, Xinxu Zhou, Fuli Liu, Zhilin Yang, Jiao Li, Lin Jiang, Ping Zhao, Xiaobin Sun, Qiong Wang","doi":"10.1186/s12876-025-04147-9","DOIUrl":"https://doi.org/10.1186/s12876-025-04147-9","url":null,"abstract":"","PeriodicalId":9129,"journal":{"name":"BMC Gastroenterology","volume":"25 1","pages":"530"},"PeriodicalIF":2.5,"publicationDate":"2025-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144697559","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sex-specific adverse effects of lipid accumulation products and cardiometabolic indices on the prevalence of gallstones: insights from the 2017-2020 national health and nutrition examination survey.","authors":"Yangyang Zheng, Xiaoli Chen, Yunpeng Ge, Haowei Shi, Shiqi Guo, Wendan Tan, Jinghai Song","doi":"10.1186/s12876-025-04099-0","DOIUrl":"https://doi.org/10.1186/s12876-025-04099-0","url":null,"abstract":"<p><strong>Background: </strong>Anthropometric measurements and lipid profiles are associated with the onset of gallstone disease, with these associations exhibiting sex-specific variations. This study investigated the association between the prevalence of gallstones and two anthropometric-lipid markers, namely Lipid Accumulation Products (LAP) and Cardiometabolic Index (CMI), while also assessing the presence of sex disparities.</p><p><strong>Methods: </strong>Data from the 2017-2020 National Health and Nutrition Examination Survey (NHANES) were analyzed, including 3,541 participants aged 20 years or older with complete information. Weighted logistic regression, restricted cubic spline modeling, and subgroup analyses were employed to assess the relationship between LAP and CMI and gallstone disease, as well as to investigate potential sex-specific differences. An analysis of the receiver operating characteristic (ROC) curve was performed to assess the prediction accuracy of indices and to determine appropriate cutoff values.</p><p><strong>Results: </strong>Elevated LAP and CMI were significantly correlated with an increased prevalence of gallstone disease among women, whereas no significant association was found in men. For each unit increase in log2-LAP, the multivariable-adjusted odds ratio (OR) for gallstone disease was 1.375 (95% CI: 1.143-1.655). For each 1-point increase in CMI, the multivariable-adjusted OR was 1.408 (95% CI: 1.098-1.806). Quartile analysis demonstrated that higher levels of LAP and CMI were significantly associated with an increased prevalence of gallstones. The associations between CMI, LAP, and the prevalence of gallstones were consistent across all subgroups (p for interaction > 0.05). LAP exhibiting the largest AUC, demonstrating high accuracy in screening for high-risk individuals for gallstone disease, comparable to traditional indices.</p><p><strong>Conclusions: </strong>The study revealed a positive association between LAP, CMI, and the prevalence of gallstones, observed exclusively among women. The findings suggest that prioritizing the reduction of LAP and CMI is crucial for preventing gallstone disease in women.</p>","PeriodicalId":9129,"journal":{"name":"BMC Gastroenterology","volume":"25 1","pages":"529"},"PeriodicalIF":2.5,"publicationDate":"2025-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144688869","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development and validation of predictive models for disease-free survival and overall survival in non-metastatic right-sided colon adenocarcinoma patients based on inflammatory and nutritional indices.","authors":"Yifan Zhang, Yun Zhou, Chengjun Wu, Cheng Ma","doi":"10.1186/s12876-025-04107-3","DOIUrl":"10.1186/s12876-025-04107-3","url":null,"abstract":"","PeriodicalId":9129,"journal":{"name":"BMC Gastroenterology","volume":"25 1","pages":"527"},"PeriodicalIF":2.5,"publicationDate":"2025-07-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12281817/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144682017","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Global burden of esophageal diseases: a comprehensive analysis of disease trends and risk factors from 1990 to 2021.","authors":"Yanbin Wei, Endian Liu, Jiafei Peng, Yanqing Liu, Xiujing Sun, Xin Yao","doi":"10.1186/s12876-025-03988-8","DOIUrl":"10.1186/s12876-025-03988-8","url":null,"abstract":"<p><strong>Background: </strong>Esophageal diseases (ED) are a common category of upper gastrointestinal disorders, mainly including gastroesophageal reflux disease (GERD), esophagitis, Barrett's esophagus, achalasia, and esophageal cancer (EC). In recent years, the high recurrence rate of GERD and poor prognosis of EC are paid more attention, collectively contributing to the global burden of ED.</p><p><strong>Methods: </strong>For this study, we systematically analyzed the global distribution of ED from 1990 to 2021, detailing the burden across different countries, regions, and socio-demographic index (SDI) levels. Furthermore, we explored temporal trends in ED burden over this period and conducted decomposition analysis, health inequality analysis, and frontier analysis. Finally, we projected trends in ED burden from 2022 to 2045, and quantify contributions of associated risk factors to disability-adjusted life years (DALYs) of EC.</p><p><strong>Results: </strong>The absolute numbers of incidence, mortality, and DALYs for GERD and EC showed increasing trends from 1990 to 2021, while their age-standardized rates (ASRs) demonstrated divergent patterns: stable for GERD and declining for EC. The highest ASRs were observed in low-middle SDI regions for GERD and high-middle SDI regions for EC, respectively, with population as a main driver. If current trends continue, the burden of GERD will continue to rise, whereas that of EC will persistently decline by 2045. In 2021, DALYs of EC were mainly attributed to smoking (36.5%) and alcohol use (16.2%).</p><p><strong>Conclusions: </strong>For GERD and EC, the global burden continued to rise and decline from 1990 to 2021, respectively. Developing targeted public health strategies in different countries and regions is crucial for alleviating the global burden of ED.</p>","PeriodicalId":9129,"journal":{"name":"BMC Gastroenterology","volume":"25 1","pages":"528"},"PeriodicalIF":2.5,"publicationDate":"2025-07-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12281767/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144682018","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The effect of neoadjuvant chemoradiation therapy in resectable pancreatic cancer was independent of intratumoral vascularization.","authors":"Tomomi Yasue, Reiko Ashida, Ryoji Takada, Kenji Ikezawa, Kazuyoshi Ohkawa, Shigenori Nagata, Teruki Teshima, Hirofumi Akita, Hidenori Takahashi, Yuichiro Doki, Hidetoshi Eguchi","doi":"10.1186/s12876-025-04108-2","DOIUrl":"10.1186/s12876-025-04108-2","url":null,"abstract":"<p><strong>Aim: </strong>Contrast-enhanced harmonic endoscopic ultrasound (CH-EUS) has promising potential in the diagnosis of pancreatic tumors, assessment of fibrosis, and prediction of chemotherapy efficacy. We hypothesize that radiation therapy might reduce variations in chemotherapeutic efficacy caused by fibrosis-induced blood flow disparities, as we explored the relationship between CH-EUS patterns and the efficacy of neoadjuvant chemoradiotherapy (NACRT) in resectable pancreatic cancer (PC).</p><p><strong>Methods: </strong>Patients with resectable PC who underwent CH-EUS followed by NACRT were retrospectively analyzed. The CH-EUS enhancement pattern was evaluated in the vascular and perfusion phases and classified according to vascularity: Group A, hypovascular in both phases; Group B, isovascular and hypovascular in the vascular and perfusion phases, respectively; and Group C, isovascular in both phases. The relationships between the CH-EUS vascular pattern and the histological response according to the Evans classification to NACRT, recurrence-free survival (RFS) and overall survival (OS) were evaluated.</p><p><strong>Results: </strong>Of the 48 enrolled patients, 31, 11, and 6 were classified into Groups A, B, and C, respectively. There was no significant difference in histopathological differentiation (p = 0.314) or the efficacy of NACRT (p = 0.282) among the groups. In addition, there was no significant difference between the groups in terms of median RFS or OS, although it was longer than previously reported.</p><p><strong>Conclusion: </strong>The histopathological efficacy of NACRT for resectable PC did not differ significantly on the basis of enhancement pattern observed on CH-EUS. NACRT may provide additional therapeutic benefit independent of blood flow considerations.</p>","PeriodicalId":9129,"journal":{"name":"BMC Gastroenterology","volume":"25 1","pages":"526"},"PeriodicalIF":2.5,"publicationDate":"2025-07-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12275297/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144667050","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The effectiveness of combining ursodeoxycholic acid with vitamin D in treating patients with primary biliary cholangitis and its impact on hepatic fibrosis: a randomized trial.","authors":"Yilihamu Abulitifu, Mierzhati Maimaiti, Fengcong Zhao, Munire Adilijiang, Wen Qian, Yongping Zhang","doi":"10.1186/s12876-025-04118-0","DOIUrl":"10.1186/s12876-025-04118-0","url":null,"abstract":"<p><strong>Objectives: </strong>To investigate the effectiveness of combining ursodeoxycholic acid (UDCA) and vitamin D (VitD) in treating patients with primary biliary cholangitis (PBC) and its impact on hepatic fibrosis.</p><p><strong>Methods: </strong>A prospective analysis was conducted on 60 treatment-naive PBC patients who were admitted to our Infectious Diseases Department and outpatient clinic from May 2021 to December 2022. All patients were taking UDCA capsules orally for one year and were randomly divided into two groups: UDCA + VitD group, which received UDCA combined with VitD (1200 IU/day) treatment, and the UDCA monotherapy group. After one year of treatment, the UDCA monotherapy group was then further stratified into two subgroups using the same method, and treatment was extended for an additional year, to further verify the role of VitD in the treatment of PBC with UDCA. Clinical manifestations, blood tests, and imaging tests were collected before and after treatment. The efficacy was evaluated using the Paris I and Barcelona standards, and the improvement of liver stiffness value was assessed according to the liver stiffness measurement (LSM) using FibroTouch.</p><p><strong>Results: </strong>After one year of treatment, the UDCA + VitD group showed statistically significant decreases in AST, GGT, ALP, Tbil, PT, INR, IgM and LSM levels, and increases in ALB and 25(OH)D levels compared to the UDCA monotherapy group. The 25(OH)D levels had a negative correlation with LSM levels. Additionally, 80.0% of patients in the UDCA + VitD group responded according to the Paris I criteria, while 86.7% responded according to the Barcelona criteria, 50.0% of patients in the UDCA monotherapy group responded according to the Paris I criteria and 63.3% responded according to the Barcelona criteria. The response rate in the UDCA + VitD group was higher than that in the UDCA monotherapy group under both criteria. In the second year of the study after the second randomization, 86.7% of patients responded according to the Paris I criteria in the UDCA + VitD subgroup, while 93.3% responded according to the Barcelona criteria. 53.3% of patients in the UDCA monotherapy subgroup responded according to the Paris I criteria and 66.7% according to the Barcelona criteria. The UDCA + VitD subgroup had a higher Paris I response rate compared with the UDCA monotherapy subgroup.</p><p><strong>Conclusions: </strong>The combination of UDCA and VitD can increase the drug response rate of UDCA and improve liver function and hepatic fibrosis in PBC patients. VitD may plays an important role in the treatment of PBC.</p>","PeriodicalId":9129,"journal":{"name":"BMC Gastroenterology","volume":"25 1","pages":"525"},"PeriodicalIF":2.5,"publicationDate":"2025-07-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12272999/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144658387","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Platelet-derived growth factor receptor-β as a non-invasive biomarker for liver fibrosis prediction in Egyptian diabetic patients with metabolic-associated fatty liver disease.","authors":"Hanaa Badran, Maha Elsabaawy, Mai Magdy, Hazem Omar, Olfat Hendy, Eman Awaad, Maymona Abd El-Wahed Al-Khalifa, Mai Abozeid","doi":"10.1186/s12876-024-03542-y","DOIUrl":"10.1186/s12876-024-03542-y","url":null,"abstract":"<p><strong>Background: </strong>Circulating platelet-derived growth factor receptor-β (PDGFRβ) has recently been found to correlate with severity of liver disease in multiple etiologies, including liver steatosis. In diabetic patients with metabolic-associated fatty liver disease (MAFLD), widely used non-invasive scoring systems, particularly the fibrosis-4 (FIB-4) score, showed unsatisfactory performance in predicting liver fibrosis severity. The aim of this study was to evaluate the productivity of serum PDGFRβ as a non-invasive biomarker of liver fibrosis in diabetic MAFLD patients.</p><p><strong>Methods: </strong>This was a population-based case-control study conducted on 50 diabetic MAFLD patients, 40 nondiabetic MAFLD patients, and 40 healthy controls. All subjects underwent complete history taking, clinical examination, anthropometric measurements, bioelectrical impedance analysis (BIA), and laboratory tests, including the PDGFRβ assay. Hepatic steatosis was assessed with magnetic resonance imaging (MRI), along with magnetic resonance elastography (MRE) for the assessment of liver fibrosis. The diagnostic performance of PDGFRβ as well as PDGFRβ + FIB-4 in prediction of significant liver fibrosis in diabetic MAFLD patients was assessed.</p><p><strong>Results: </strong>Liver steatosis and significant liver fibrosis (≥ F2) were significantly higher in diabetic MAFLD patients than in nondiabetics. PDGFRβ levels were significantly higher in both diabetic and nondiabetic MAFLD patients compared to controls. Sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) of PDGFRβ to predict significant liver fibrosis in diabetic MAFLD patients were 85%, 93.33%, 89.5%, and 90.3%, respectively, at a cutoff > 2.54, and were 85.71%, 51.52%, 27.3%, and 94.4% at a cutoff > 1.59 in nondiabetics. Sensitivity, specificity, PPV, and NPV of (PDGFRβ at a cutoff > 2.54 + FIB-4 at a cutoff > 1.17) to predict significant liver fibrosis in diabetic MAFLD patients were 100%. PDGFRβ was the only independent predictor of significant liver fibrosis in diabetic MAFLD (p = 0.006).</p><p><strong>Conclusions: </strong>PDGFRβ proved efficacy as a noninvasive biomarker in the prediction of significant liver fibrosis (≥ F2) in diabetic MAFLD patients.</p>","PeriodicalId":9129,"journal":{"name":"BMC Gastroenterology","volume":"25 1","pages":"524"},"PeriodicalIF":2.5,"publicationDate":"2025-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12272993/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144658386","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}